跳至主要内容
临床试验/NCT05273385
NCT05273385
终止
不适用

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 16 人2022年10月10日

概览

阶段
不适用
干预措施
Nanodropper
疾病 / 适应症
Glaucoma
发起方
University of California, San Francisco
入组人数
16
试验地点
1
主要终点
Intraocular Pressure (IOP) at Baseline
状态
终止
最后更新
上个月

概览

简要总结

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

详细描述

The proposed study strives to demonstrate the non-inferiority of using Nanodropper to lower IOP in glaucoma patients compared to standard of care (SOC) eye drops in a randomized trial. Primary Aim: Demonstrate non-inferiority of using Nanodropper to lower IOP compared to standard of care eye drops in glaucoma patients. Stable glaucoma participants and ocular hypertension participants of ages 18+ will be randomized to either use Nanodropper for eye drop administration in both eyes OR administer drops regularly (standard of care) in both eyes. Participants will be followed-up at 1 month and 3 months.

注册库
clinicaltrials.gov
开始日期
2022年10月10日
结束日期
2024年12月10日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

入排标准

入选标准

  • 18 years old or older
  • Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
  • Use of prostaglandin analogue (PGA) eye drop
  • Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)

排除标准

  • Uncontrolled glaucoma
  • Have had eye surgery (including laser procedures) within the past six months
  • Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
  • Use of non-PGA class of IOP-lowering medication

研究组 & 干预措施

Nanodropper

Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.

干预措施: Nanodropper

Standard of Care Dropper

Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.

结局指标

主要结局

Intraocular Pressure (IOP) at Baseline

时间窗: At Baseline

IOP measurement of the eye will be collected at the baseline visit using routine methods including Goldman applanation tonometry and pneumotonometer.

Intraocular Pressure (IOP) at Month 1

时间窗: 1 month

IOP measurement of the eye will be collected at the Month 1 visit using routine methods including Goldman applanation tonometry and pneumotonometer.

Intraocular Pressure (IOP) at Month 3

时间窗: 3 months

IOP measurement of the eye will be collected at the month 3 visit using routine methods including Goldman applanation tonometry and pneumotonometer.

次要结局

  • Survey(3 months)
  • Conjunctival Grading at Baseline(At baseline)
  • Conjunctival Grading at Month 3(3 months)

研究点 (1)

Loading locations...

相似试验